Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.

In a double-blind 6 month controlled trial conducted in 50+ year olds with memory decline, investigating 1 or 4g curcumin daily (against placebo).

Serum amyloid-beta pigmentation and isoprostanes did not differ between groups, although a non-significant trend was shown for serum levels of AB to rise.